amylyx glp-1 Today, we announced the nomination of an investigational, long-acting receptor antagonist as our new development candidate, identified in collaboration with Gubra A/S. Learn more about this exciting update: https://t.co/yXStYTN9Kw Amylyx Pharmaceuticals Announces Acquisition of
Description
Key Takeaway: Mazdutide demonstrated superiority in combined glycemic control and weight loss
As fatty liver disease continues to drive downstream costs, this signal is getting serious attention
Reuters and Stanford published the same finding on April 10
Naturally support your GLP-1 function with no side-effects - turning off your food noise &
More randomized data will be required to arrive at conclusive evidence.
Merola, M.D
